BioSpace News Archive

Kimball Electronics, Inc. was honored for achieving the Highest Overall Customer Ratings in four categories of CIRCUITS ASSEMBLY’S 2023 Service Excellence Awards: Dependability/Timely Delivery, Technology, Value for the Price, and Manufacturing Quality.

Regeneron Pharmaceuticals, Inc. announced a five-year, $5 million strategic investment to bolster Nashville, Tennessee’s science, technology, engineering and mathematics ecosystem through high-quality, equitable engagement programs for students and science teachers.

MiRus® announced that it has received FDA 510(k) clearance of the CYGNUS™ MoRe® Anterior Cervical Plate and MiRus® 3DR™ Lateral Lumbar Interbody Fusion System with Integrated MoRe® plate fixation, both being the narrowest and thinnest plating system amongst all plates on the global spine market.

Candel Therapeutics, Inc. today announced that Nature published results from the ongoing first-in-human phase 1 investigator-sponsored clinical trial of CAN-3110, a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate, in patients with recurrent high-grade glioma (HGG), of which 86.7% were glioblastoma, that had returned after standard of care (SoC) treatment.

NexImmune, Inc. announced that the Board of Directors and stockholders of the Company approved a 1-for-25 reverse stock split of the Company’s common stock at a special meeting of the Company held on October 17, 2023.

Mablink Bioscience (“Mablink”), a pre-clinical biotechnology company pioneering the development of next-generation antibody-drug conjugates (ADCs) via its PSARLink™ proprietary platform, today announced an agreement to be acquired by Eli Lilly and Company (“Lilly”).

Y-mAbs Therapeutics, Inc. announced that its Board of Directors has appointed Michael Rossi as President and Chief Executive Officer and a member of the Board of Directors with an expected start date of November 6, 2023.

Inhibrx, Inc., a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced it will be presenting at the following upcoming scientific conferences.

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, Oct. 25, 2023 to discuss the company’s third quarter financial results as well as initial clinical data related to ALKS 2680, the company’s novel, investigational orexin 2 receptor agonist in development for the treatment of narcolepsy, that will be presented at World Sleep Congress.

Amedisys, Inc., a leading provider of home health, hospice and high-acuity care in the home, is proud to celebrate National Quality Week October 15-21, 2023.